Anteris Technologies Global Corp
Company Profile
Business description
Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.
Contact
9 Sherwood Road
Level 3, Suite 302
ToowongQLD4066
AUST: +61 731523200
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Why I dislike dividend stocks
stocks
Chart of the Week: Ramsay Health Care margins to rebound
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,375.90 | 19.70 | 0.21% |
| CAC 40 | 8,077.00 | 157.38 | 1.99% |
| DAX 40 | 24,181.37 | 55.57 | -0.23% |
| Dow JONES (US) | 46,253.31 | 17.15 | -0.04% |
| FTSE 100 | 9,424.75 | 28.02 | -0.30% |
| HKSE | 25,722.65 | 187.95 | -0.73% |
| NASDAQ | 22,670.08 | 148.38 | 0.66% |
| Nikkei 225 | 48,246.69 | 574.02 | 1.20% |
| NZX 50 Index | 13,389.10 | 81.70 | 0.61% |
| S&P 500 | 6,671.06 | 26.75 | 0.40% |
| S&P/ASX 200 | 9,068.40 | 18.20 | 0.20% |
| SSE Composite Index | 3,902.70 | 9.51 | -0.24% |